Abstract: There is provided an inhibitor that inhibits casein kinase 1? and casein kinase 1?, and thus, there is also provided a pharmaceutical agent useful for the treatment and/or prevention of a disease, with the pathological condition of which the mechanism of activation of casein kinase 1? or casein kinase 1? is associated. Particularly, the above-described inhibitor is used to provide a pharmaceutical agent useful for the treatment of circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer.

Abstract: There is provided a novel oxazolone derivative having inhibitory activity against casein kinase 1? and casein kinase 1?. In addition, the present inhibitor inhibits casein kinase 1? and casein kinase 1?, and thus there is also provided a pharmaceutical agent useful for the treatment and/or prevention of diseases, with the pathological conditions of which the activation mechanism of casein kinase 1? or casein kinase 1? is associated. There is further provided a pharmaceutical agent useful for the treatment of, particularly, circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer. An inhibitor of casein kinase 1? and casein kinase 1? comprising, as an active ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: wherein X represents a halogen atom which is fluorine, chlorine, bromine or iodine.

Abstract: There is provided a novel oxazolone derivative having inhibitory activity against casein kinase 1? and casein kinase 1?. In addition, the present inhibitor inhibits casein kinase 1? and casein kinase 1?, and thus there is also provided a pharmaceutical agent useful for the treatment and/or prevention of diseases, with the pathological conditions of which the activation mechanism of casein kinase 1? or casein kinase 1? is associated. There is further provided a pharmaceutical agent useful for the treatment of particularly, circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer. An inhibitor of casein kinase 1? and casein kinase 1? comprising, as an act ingredient, an oxazolone derivative represented by the following general formula (1), a salt thereof, a solvate thereof, or a hydrate thereof: wherein X represents a halogen atom (which may be any one of a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom).

Abstract: There is provided an inhibitor that inhibits casein kinase 1? and casein kinase 1?, and thus, there is also provided a pharmaceutical agent useful for the treatment and/or prevention of a disease, with the pathological condition of which the mechanism of activation of casein kinase 1? or casein kinase 1? is associated. Particularly, the above-described inhibitor is used to provide a pharmaceutical agent useful for the treatment of circadian rhythm disorder (including sleep disorder), central neurodegenerative disease, and cancer.

Abstract: A case for receiving and dispensing pills, having an optional top cover having a forward edge and a rearward edge, an optional bottom cover having a forward edge and a rearward edge, a spine extending between the top cover and the bottom cover, to which the top cover and the bottom cover are affixed at the rearward edges thereof, and at least one sleeve containing a plurality of pills secured within the sleeve and adapted to be dispensed therefrom, the sleeve having a forward edge and a rearward edge and being attached to the spine at the rearward edge thereof between the top cover and the bottom cover.

Abstract: It is intended to provide novel polypeptides which specifically inhibit the activity of a mechano-sensitive channel; and mechano-sensitive channel inhibitors or remedies for atrial fibrillation containing these polypeptides or salts thereof. The above objects can be achieved by using polypeptides having amino acid sequences represented by SEQ ID NO: 1 (TVP003), SEQ ID NO:2 (TVP004) and SEQ ID NO:3 (TVP005), salts of these polypeptides, and mechano-sensitive channel inhibitors or remedies for atrial fibrillation containing the same.

Abstract: A needle dispensing system including a pen-type hypodermic syringe having a threaded end that is suitable for mating with a needle assembly having a threaded portion that is complementary to the threaded end of the syringe and located within a closed pod. A hand tool is provided for controlling the pod that includes a collet sized so as to releasably grip a portion of the closed pod for opening. The hand tool also includes a radiused guard that helps to prevent inadvertent needle sticks during use, and a biased release button the actuation of which causes the opened pod to be released from the collet. A hand tool is also provided for controlling a container holding a disposable needle assembly that includes a housing that supports a collet that is sized so as to releasably grip a portion of the container for opening, and a biased release button the actuation of which causes the opened pod to be released from the collet.

Abstract: It is intended to provide novel polypeptides which specifically inhibit the activity of a mechano-sensitive channel; and mechano-sensitive channel inhibitors or remedies for atrial fibrillation containing these polypeptides or salts thereof. The above objects can be achieved by using polypeptides having amino acid sequences represented by SEQ ID NO:1 (TVP003), SEQ ID NO:2 (TVP004) and SEQ ID NO:3 (TVP005), salts of these polypeptides, and mechano-sensitive channel inhibitors or remedies for atrial fibrillation containing the same.

Abstract: A pill case includes a pill holding portion having at least one pill holding compartment for receiving and retaining a pill, and a retractable display assembly in operative association with the pill holding portion, wherein the retractable display assembly includes a retractable card having at least one surface defining a display area for displaying indicia which can be read by a user, the retractable card is being movable to a non-retracted position in which the retractable card is at least substantially uncovered with respect to the pill holding portion and an assembly for preventing the retractable card from disengaging from the retractable display assembly.

Abstract: A case for receiving and dispensing pills, having an optional top cover having a forward edge and a rearward edge, an optional bottom cover having a forward edge and a rearward edge, a spine extending between the top cover and the bottom cover, to which the top cover and the bottom cover are affixed at the rearward edges thereof, and at least one sleeve containing a plurality of pills secured within the sleeve and adapted to be dispensed therefrom, the sleeve having a forward edge and a rearward edge and being attached to the spine at the rearward edge thereof between the top cover and the bottom cover.

Abstract: A pill container includes a plurality of compartments arranged radially from one another, each of the plurality of compartments adapted for receiving and retaining at least one pill and reversibly secured by a corresponding closure; and a movable tab located in each of the plurality of compartments, each movable tab is configured to reversibly move from a first position to a second position within the corresponding compartment to partition the compartment into two discrete compartment portions.

Abstract: A light transmitting device for attachment to a stethoscope headpiece which provides for reversible engagement of the device to the headpiece so that the same can be removed such as for repairs or replacement of batteries. The transmitting device provides a source of light without interfering with the operation of the stethoscope and can be provided without retooling the stethoscope to accommodate a source of light.